European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations

ABBOTT PARK, Ill., May 24, 2023 /PRNewswire/ -- New data presented from an investigator-sponsored European trial found managing indicated¹ heart failure patients with Abbott's CardioMEMS™ HF System resulted in a significant¹ improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor. The MONITOR-HF trial also resulted in a significant 44% reduction in heart failure-related hospitalizations among chronic heart failure patients who used guideline-directed medical therapy (GDMT). GDMT refers to the European and U.S. guidelines for heart failure management² that uses a combination of up to four heart medications. MONITOR-HF is the third randomized, controlled clinical trial globally to show a significant health benefit and quality-of-life improvement for heart failure patients using the CardioMEMS HF System.